Skip to main content
OpenTrials

Clinical trial condition

Gonadal Disorders

Explore clinical trials studying Gonadal Disorders. Study availability and eligibility vary by location and protocol.

4,158 public trials 780 recruiting studies
Refine in advanced search Browse all conditions

Gonadal Disorders trial results

Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

NCT04491942

Conditions
Adenoma, Adnexal Diseases, Advanced Bile Duct Carcinoma, +72 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York, United States
View Trial Details
Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

NCT04616534

Conditions
Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +40 more
Locations
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

NCT05554367

Conditions
Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, +21 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • UC San Diego Health System - Encinitas Encinitas, California, United States
View all 266 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

NCT02345265

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
View all 20 locations
View Trial Details
Active, Not Recruiting

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

NCT01366144

Conditions
Adnexal Diseases, Breast Carcinoma, Breast Diseases, +70 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02595892

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +18 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • UC San Diego Medical Center - Hillcrest San Diego, California, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02627443

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +26 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • UF Health Cancer Institute - Gainesville Gainesville, Florida, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02839707

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +33 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 920 locations
View Trial Details
Active, Not Recruiting

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02101775

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +33 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Decatur Memorial Hospital Decatur, Illinois, United States
View all 16 locations
View Trial Details

Related conditions